mTBI Mechanisms of Action of HBO2 for Persistent Post-Concussive Symptoms (BIMA)
Brain Injury and Mechanisms of Action of HBO2 for Persistent Post-Concussive Symptoms After Mild Traumatic Brain Injury (BIMA) Protocol
Sponsor: U.S. Army Medical Research and Development Command
Listed as NCT01611194, this PHASE2 trial focuses on Post-Concussion Syndrome and Traumatic Brain Injury With Brief Loss of Consciousness and remains completed. Sponsored by U.S. Army Medical Research and Development Command, it has been updated 10 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Dec 2018 — Aug 2019 [monthly]
Completed PHASE2
Phase: NA → PHASE2
▶ Show 5 earlier versions
-
Jun 2018 — Dec 2018 [monthly]
Completed NA
-
Oct 2017 — Jun 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jun 2017 — Oct 2017 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Sep 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- U.S. Army Medical Research and Development Command
For direct contact, visit the study record on ClinicalTrials.gov .